When was Lantern Pharma founded?

Lantern Pharma was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Lantern Pharma located?

Lantern Pharma is headquartered in Dallas, United States.

How many employees does Lantern Pharma have?

As of Sep 30, 2026, the latest employee count at Lantern Pharma is 31.

Is Lantern Pharma a funded company?

Lantern Pharma is a funded company, having raised a total of $7.12M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 28, 2014.

When was the latest funding round of Lantern Pharma?

Lantern Pharma's latest funding was a $***** Grant (prize money) round on Jan 03, 2022, with participation from 1 investor.

Where does Lantern Pharma rank among its competitors?

Lantern Pharma ranks 106th amongst 3571 active competitors, of which 1163 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Lantern Pharma?

Lantern Pharma's top competitors include Jazz Pharmaceuticals, BeiGene and Natera. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Lantern Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Lantern Pharma is a public company based in Dallas (United States), founded in 2013 by Arun Asaithambi. It operates as a Developing drug and companion diagnostics for multi-drug resistant cancers. Lantern Pharma has raised $7.12M in funding from Green Park & Golf Ventures and Bios Partners. The company has 3571 active competitors, including 1163 funded and 818 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Natera.

Company Details

Developing drug and companion diagnostics for multi-drug resistant cancers. Its approach is to biomarker-biased genetic screening to identify and treat patients that would benefit most from our drugs. Its lead candidate is Irovfulven-1, a new class of anti-tumor agents to treat multi-drug-resistant cancers.

Website: www.lanternpharma.com/
Social
Email ID: *****@lanternpharma.com
Phone Number: +1 **********

Key Metrics

Founded Year

2013

Location

Dallas, United States

Stage

Public

Total Funding

$7.12M in 5 rounds

Latest Funding Round

Grant (prize money), Jan 03, 2022, $*****

Investors

Green Park & Golf Ventures & 4 more

Ranked

106^th among 3571 active competitors

Employee Count

31 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 6151 more

Exit Details

Public

View Lantern Pharma's full profile

Lantern Pharma is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Lantern Pharma Inc. CIN: 32052429233 , United States, Active	Feb 07, 2020	-	-	-
Lantern Pharma Inc. CIN: 1763950 , United States, Active	Jan 14, 2020	-	20 (As on Dec 31, 2024)	-
Lantern Pharma, Inc. CIN: 7801204 , United States, Active		-	14 (As on Dec 31, 2021)	-

Lantern Pharma got listed on Jun 11, 2020.

Click here to take a look at Lantern Pharma's IPO in detail

Lantern Pharma has raised a total funding of $7.12M over 5 rounds. Its first funding round was on Aug 28, 2014. Its latest funding round was a Grant (prize money) round on Jan 03, 2022 for $*****. 1 investor participated in its latest round. Lantern Pharma has 5 institutional investors.

Here is the list of recent funding rounds of Lantern Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 03, 2022	8425884	Grant (prize money)	8527602	4016617	4610304	3671392
Mar 18, 2019	3387136	Series A	7344740	8814823	3714164	3080929
May 02, 2017	7949240	Series A	7371353	8302907	Bios Partners & 1 more	5837973

Access funding benchmarks and valuations. Sign up today!

View details of Lantern Pharma's funding rounds and investors

The founders of Lantern Pharma is Arun Asaithambi.

Here are the details of Lantern Pharma's key team members:

Arun Asaithambi: Co-Founder of Lantern Pharma and founder of 2 other companies, Covid 19 Monitoring and Intuition Systems. They serve on the board of 1 company.
Contact Info: 1 email address

View details of Lantern Pharma's Founder profiles and Board Members

Lantern Pharma's employee count trend

Lantern Pharma has 31 employees as of Sep 26. Here is Lantern Pharma's employee count trend over the years:

Uncover Lantern Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lantern Pharma include Jazz Pharmaceuticals, BeiGene and Natera. Here is the list of Top 10 competitors of Lantern Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	77/100
4th	LifeCell 2004, Chennai (India), Series B	A stem cell banking company specializing in cord blood and tissue preservation	$61.2M	Orbimed, Helion Venture Partners & 74 others	74/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
106th	Lantern Pharma 2013, Dallas (United States), Public	Developing drug and companion diagnostics for multi-drug resistant cancers	$7.12M	Bios Partners, Green Park & Golf Ventures ... & 3 others	62/100